Current Report Filing (8-k)
November 03 2016 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): November 3, 2016
INTERCEPT PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-35668
|
|
22-3868459
|
(state or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
450 W. 15
th
Street, Suite
505
New York, New York
|
|
|
|
10011
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (646) 747-1000
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02 Results of Operations and Financial Condition.
On November 3, 2016, Intercept Pharmaceuticals,
Inc. (the “Company”) announced its results for the nine months and quarter ended September 30, 2016. A copy of the
Company’s press release containing such announcement is attached hereto as Exhibit 99.1. The information in the press release
is incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.
Except as shall be expressly set forth by
specific reference, the information contained or incorporated by reference in this Item 2.02 shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that
section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibits.
Exhibit No.
|
Description
|
99.1
|
Press Release dated November 3, 2016*
|
|
*Exhibit 99.1 is furnished as part of this Current Report on Form 8-K
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
INTERCEPT PHARMACEUTICALS, INC.
|
|
|
|
Date: November 3, 2016
|
|
|
|
/s/ Mark Pruzanski
|
|
|
|
|
Mark Pruzanski, M.D.
President and Chief Executive Officer
|
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Sep 2023 to Sep 2024